NCT03805594Prostate cancerpembrolizumabNivolumabIpilimumabCRPC177Lu-PSMA
…with PD-1 blockade, pembrolizumab, in a phase 1 clinical trial (NCT03805594).4 However, the schedule by which these treatments should be co…
1articles mentioning institutions
1institution mentions
1distinct institutions extracted
0%of mentions human-reviewed
Active filtersEntity: NCT03805594 ×
NCT03805594
This institution is selected. Its supporting articles are shown below.